Astrocytoma News and Research

RSS
Researchers use light-activated nanozymes to treat aggressive brain tumors

Researchers use light-activated nanozymes to treat aggressive brain tumors

Clinical trial tests a newer, targeted therapy for IDH mutant astrocytoma

Clinical trial tests a newer, targeted therapy for IDH mutant astrocytoma

Pomegranate’s hidden fiber-bound polyphenols significantly increase total antioxidant capacity

Pomegranate’s hidden fiber-bound polyphenols significantly increase total antioxidant capacity

Innovative laser procedure offers new hope for recurrent brain tumors

Innovative laser procedure offers new hope for recurrent brain tumors

Researchers uncover mechanisms of three mismatch repair deficient high-grade glioma subtypes

Researchers uncover mechanisms of three mismatch repair deficient high-grade glioma subtypes

New combination treatment offers significant benefits for people with recurring grade 3 astrocytoma

New combination treatment offers significant benefits for people with recurring grade 3 astrocytoma

New combination treatment helps people with recurring grade 3 astrocytoma, trial shows

New combination treatment helps people with recurring grade 3 astrocytoma, trial shows

Glutamate receptors found to drive pediatric brain tumor development

Glutamate receptors found to drive pediatric brain tumor development

Niigata University team reports novel treatment for IDH2-mutant brainstem glioma

Niigata University team reports novel treatment for IDH2-mutant brainstem glioma

From discovery to approval: Vorasidenib approved by FDA for treatment of IDH-mutant gliomas

From discovery to approval: Vorasidenib approved by FDA for treatment of IDH-mutant gliomas

Elias family's gift to MD Anderson will help advance brain tumor and cancer neuroscience research

Elias family's gift to MD Anderson will help advance brain tumor and cancer neuroscience research

Study may help advance data on oncolytic adenovirus mediated double suicide-gene therapy for high-grade brain tumors

Study may help advance data on oncolytic adenovirus mediated double suicide-gene therapy for high-grade brain tumors

Mays Cancer Center conducts clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma

Mays Cancer Center conducts clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma

People with a rare form of brain and spinal cord cancer have poor prognosis, research reports

People with a rare form of brain and spinal cord cancer have poor prognosis, research reports

NQO2 gene as a novel potential target in Parkinson’s disease

NQO2 gene as a novel potential target in Parkinson’s disease

Breakthrough technology identifies rare brain tumor cell "spies" disguised as normal cells

Breakthrough technology identifies rare brain tumor cell "spies" disguised as normal cells

Effect of COVID-19 mRNA vaccine on in vitro glial cells of the brain studied by Raman spectroscopy and imaging

Effect of COVID-19 mRNA vaccine on in vitro glial cells of the brain studied by Raman spectroscopy and imaging

Children’s National performs first-ever HIFU surgery on a pediatric patient with neurofibromatosis

Children’s National performs first-ever HIFU surgery on a pediatric patient with neurofibromatosis

WHO's new List of Essential Medicines prioritizes access to diabetes and cancer treatments

WHO's new List of Essential Medicines prioritizes access to diabetes and cancer treatments

Study in dogs may lead to better understanding of how gliomas affect the immune system

Study in dogs may lead to better understanding of how gliomas affect the immune system

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.